Antibody Response in Immunocompromised Patients After the Administration of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Vaccine BNT162b2 or mRNA-1273: A Randomized Controlled Trial
Benjamin Speich,Frédérique Chammartin,Irene A Abela,Patrizia Amico,Marcel P Stoeckle,Anna L Eichenberger,Barbara Hasse,Dominique L Braun,Macé M Schuurmans,Thomas F Müller,Michael Tamm,Annette Audigé,Nicolas J Mueller,Andri Rauch,Huldrych F Günthard,Michael T Koller,Alexandra Trkola,Matthias Briel,Katharina Kusejko,Heiner C Bucher,Swiss HIV Cohort Study and the Swiss Transplant Cohort Study,I A Aebi-Popp,K Anagnostopoulos,A Battegay,M Bernasconi,E Braun,D L Bucher,H C Calmy,A Cavassini,M Ciuffi,A Dollenmaier,G Egger,M Elzi,L Fehr,J Fellay,J Furrer,H Fux,C A Günthard,A Haerry,B Hirsch,H H Hoffmann,M Hösli,I Huber,M Kahlert,L Keiser,O Klimkait,T Kouyos,R D Kovari,H Kusejko,G Martinez de Tejada,B Marzolini,C Metzner,K J Müller,N Nemeth,J Nicca,D Paioni,P Pantaleo,G Perreau,M Rauch,P Speck,R Stöckle,P Trkola,A Wandeler,G Yerly,Andres Axel,John David Aubert,Vanessa Banz,Beckmann Sonja,Guido Beldi,Christoph Berger,Ekaterine Berishvili,Isabelle Binet,Pierre Yves Bochud,Sanda Branca,Thierry Carrel,Emmanuelle Catana,Yves Chalandon,Sabina De Geest,Olivier De Rougemont,Michael Dickenmann,Joëlle Lynn Dreifuss,Michel Duchosal,Thomas Fehr,Sylvie Ferrari-Lacraz,Nicola Franscini,Christian Garzoni,Paola Gasche Soccal,Christophe Gaudet,Déla Golshayan,Nicolas Goossens,Karine Hadaya,Jörg Halter,Dominik Heim,Christoph Hess,Sven Hillinger,Hans Hirsch,Patricia Hirt,Günther Hofbauer,Uyen Huynh-Do,Franz Immer,Michael Koller,Mirjam Laager,Bettina Laesser,Roger Lehmann,Alexander Leichtle,Christian Lovis,Oriol Manuel,Hans Peter Marti,Pierre Yves Martin,Michele Martinelli,Valérie McLin,Katell Mellac,Aurélia Merçay,Karin Mettler,Nicolas Mueller,Antonia Müller,Ulrike Müller-Arndt,Beat Müllhaupt,Mirjam Nägeli,Graziano Oldani,Manuel Pascual,Klara Posfay-Barbe,Juliane Rick,Anne Rosselet,Simona Rossi,Silvia Rothlin,Frank Ruschitzka,Thomas Schachtner,Urs Schanz,Stefan Schaub,Aurelia Schnyder,Macé Schuurmans,Thierry Sengstag,Federico Simonetta,Susanne Stampf,Jürg Steiger,Guido Stirniman,Ueli Stürzinger,Christian Van Delden,Jean Pierre Venetz,Jean Villard,Julien Vionnet,Madeleine Wick,Markus Wilhlem,Patrick Yerly
DOI: https://doi.org/10.1093/cid/ciac169
2022-08-24
Abstract:Background: BNT162b2 by Pfizer-BioNTech and mRNA-1273 by Moderna are the most commonly used vaccines to prevent severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infections. Head-to-head comparison of the efficacy of these vaccines in immunocompromised patients is lacking. Methods: Parallel, 2-arm (allocation 1:1), open-label, noninferiority randomized clinical trial nested into the Swiss HIV Cohort Study and the Swiss Transplant Cohort Study. People living with human immunodeficiency virus (PLWH) or solid organ transplant recipients (SOTR; ie, lung and kidney) from these cohorts were randomized to mRNA-1273 or BNT162b2. The primary endpoint was antibody response to SARS-CoV-2 spike (S1) protein receptor binding domain (Elecsys Anti-SARS-CoV-2 immunoassay, Roche; cutoff ≥0.8 units/mL) 12 weeks after first vaccination (ie, 8 weeks after second vaccination). In addition, antibody response was measured with the Antibody Coronavirus Assay 2 (ABCORA 2). Results: A total of 430 patients were randomized and 412 were included in the intention-to-treat analysis (341 PLWH and 71 SOTR). The percentage of patients showing an immune response was 92.1% (95% confidence interval [CI]: 88.4-95.8; 186/202) for mRNA-1273 and 94.3% (95% CI: 91.2-97.4; 198/210) for BNT162b2 (difference: -2.2%; 95% CI: -7.1 to 2.7), fulfilling noninferiority of mRNA-1273. With the ABCORA 2 test, 89.1% had an immune response to mRNA-1273 (95% CI: 84.8-93.4; 180/202) and 89.5% to BNT162b2 (95% CI: 85.4-93.7; 188/210). Based on the Elecsys test, all PLWH had an antibody response (100.0%; 341/341), whereas for SOTR, only 60.6% (95% CI: 49.2-71.9; 43/71) had titers above the cutoff level. Conclusions: In immunocompromised patients, the antibody response of mRNA-1273 was noninferior to BNT162b2. PLWH had in general an antibody response, whereas a high proportion of SOTR had no antibody response.